Research map: Refining risk-stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches

Back to the article

Papers in this map

  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms · Rita Alaggio · 2022 · 4022 citations · Cited by this paper
  2. Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think? · 2026 · Related
  3. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma · Michael Wang · 2020 · 1874 citations · Cited by this paper
  4. Challenges faced by women and girls with hemophilia/Carriers: an expert call for closing the diagnosis gap · 2026 · Related
  5. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma · Michael Wang · 2013 · 1710 citations · Cited by this paper
  6. Social challenges and support needs of patients with hemophilia in Pakistan: a qualitative exploratory study · 2026 · Related
  7. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee · Elı́as Campo · 2022 · 1607 citations · Cited by this paper
  8. Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs · 2026 · Related
  9. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma · Eva Hoster · 2007 · 990 citations · Cited by this paper
  10. A Review of Disparities in Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma · 2026 · Related
  11. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma · David Matthew Kurtz · 2018 · 506 citations · Cited by this paper
  12. Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison · 2026 · Related
  13. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study · Mark J. Roschewski · 2015 · 467 citations · Cited by this paper
  14. An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor) · 2026 · Related
  15. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy · Christian Winther Eskelund · 2017 · 411 citations · Cited by this paper
  16. Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing · 2026 · Related
  17. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network · Eva Hoster · 2016 · 372 citations · Cited by this paper
  18. Apparent plateaus during iron chelation in transfusion-dependent β-thalassemia: interpretation and clinical implications · 2026 · Related
  19. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study · Michael Wang · 2022 · 336 citations · Cited by this paper
  20. Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia · 2026 · Related
  21. Postibrutinib outcomes in patients with mantle cell lymphoma · Peter Martin · 2016 · 293 citations · Cited by this paper
  22. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study · Christiane Pott · 2009 · 273 citations · Cited by this paper
  23. Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features · Alba Navarro · 2012 · 257 citations · Cited by this paper
  24. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma · Lina Nygren · 2012 · 167 citations · Cited by this paper
  25. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma · Christiane Pott · 2005 · 165 citations · Cited by this paper
  26. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma · Marie‐Hélène Delfau‐Larue · 2015 · 162 citations · Cited by this paper
  27. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network · Martin Dreyling · 2024 · 152 citations · Cited by this paper
  28. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL) · Emanuele Zucca · 1994 · 151 citations · Cited by this paper
  29. Mantle-Cell Lymphoma · James Olen Armitage · 2022 · 147 citations · Cited by this paper
  30. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study · Simone Ferrero · 2019 · 140 citations · Cited by this paper
  31. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study · Lena Nordström · 2014 · 138 citations · Cited by this paper
  32. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study · Michael Wang · 2023 · 111 citations · Cited by this paper
  33. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study · Carlo Visco · 2020 · 104 citations · Cited by this paper
  34. Time to progression of mantle cell lymphoma after high‐dose cytarabine‐based regimens defines patients risk for death · Carlo Visco · 2018 · 73 citations · Cited by this paper
  35. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Toby Andrew Eyre · 2025 · 72 citations · Cited by this paper
  36. First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101) · John Francis Seymour · 2023 · 70 citations · Cited by this paper
  37. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma · Michael Wang · 2025 · 63 citations · Cited by this paper
  38. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy · Irl Brian Greenwell · 2018 · 61 citations · Cited by this paper
  39. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up · Martin Dreyling · 2022 · 61 citations · Cited by this paper

Source: OpenAlex (CC0)